Corvus Pharmaceuticals Overview
Pro stress-test →Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies focused on ITK inhibition for cancer and immune diseases. The company's lead program, soquelitinib, is a first-in-class oral ITK inhibitor showing promising Phase 1 data in atopic dermatitis with 75% EASI-75 response rates.
Strategic Profile
Pro stress-test →Corvus is pioneering ITK inhibition as a differentiated immunotherapy approach with a diversified pipeline including ciforadenant for renal cell cancer and mupadolimab for lung cancer. The company leverages strategic partnerships including a 49.7% equity stake in Angel Pharmaceuticals for greater China market expansion.
Competitive Landscape
Pro stress-test →Corvus competes in the immunotherapy space against established players like Merck, Bristol-Myers Squibb, and Regeneron developing checkpoint inhibitors and other immunomodulators. However, its first-in-class ITK inhibitor approach differentiates it from traditional PD-1/PD-L1 and CTLA-4 therapies, targeting a distinct mechanism of immune regulation.
Industry Context
Corvus Pharmaceuticals operates in Biopharmaceuticals - Immunotherapy and Oncology.
Key facts
Founded: 2014 · Headquarters: South San Francisco, California